Genentech's June 2nd, 2013 announcement that its blockbuster drug, Avastin (bevacizumab), failed to prolong life in newly-diagnosed glioblastoma multiforme (GBM) patients was a sharp reminder of the severity of the disease and the real need for solid hope for patients battling the dreaded brain cancer. With U.S. incidence of 2 to 3 persons per 100,000 annually diagnosed with GBM, prognosis is currently poor with a median survival rate of 15 months and a 5 year survival rate of just 4%. Current treatment options are limited with U.S. approvals limited to Temozolomide, approved in 2005 for newly-diagnosed GBM; Avastin, approved in 2009 for recurrent and previously-treated GBM; Prolifeprosan 20 with Carmustine Implant, approved in 1997 as part of the initial treatment...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|